Context Therapeutics, Inc. (CNTX)
NASDAQ:CNTX
Want to see CNTX full AI Analyst Report?
CNTX Stock Chart & Stats
$2.43
$0.09(8.26%)
At close: 4:00 PM EST
$2.43
$0.09(8.26%)
Day’s Range― - ―
52-Week Range$0.56 - $3.62
Previous CloseN/A
Volume293.07K
Average Volume (3M)1.80M
Market Cap
$58.06M
Enterprise Value$881.33K
Total Cash (Recent Filing)$54.53M
Total Debt (Recent Filing)$282.42K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding91,879,170
10 Day Avg. Volume4,071,377
30 Day Avg. Volume1,800,357
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.94
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$5.67Price Target Upside133.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Advancement (Fast Track)Fast Track for CTIM-76 is a structural regulatory benefit that can shorten development timelines and improve FDA engagement. Over 2-6 months it materially reduces regulatory friction, enhances the program's de-risking profile for partners and investors, and increases potential speed to later-stage trials.
Secured Full Economic Rights To AntibodiesAcquiring irrevocable, royalty-free licenses eliminates future milestone/royalty obligations and counterparty termination risk. This structural shift improves economics, control and strategic optionality for CT-202's development and partner negotiations, supporting long-term value capture.
Low Leverage And Near-Term RunwayA conservatively levered balance sheet and meaningful equity provide financial flexibility versus highly levered peers. Combined with disclosed runway into mid-2027, this structural cushion reduces immediate refinancing pressure and gives time to advance clinical readouts or strike partnerships.
Bears Say
No Revenue; Widening LossesContext is a development-stage biotech with no product revenue and materially widening losses over multiple years. Persistent negative earnings mean intrinsic value depends on clinical success; this structural lack of operating income increases reliance on external capital and amplifies binary program risk.
Sustained Cash BurnOperating and free cash flows are negative every period, with cash burn increasing year-over-year. This durable outflow pattern limits self-funding capacity, forces near-term financing or partnerships, and raises dilution risk unless pipeline catalysts reliably convert into value or third-party capital is secured.
Governance And Legal DisruptionA Delaware ruling that invalidated charter provisions and a subsequent mootness payment signal governance shortcomings that required corrective action and cash expense. Such structural governance issues can distract management, raise stakeholder uncertainty and modestly constrain strategic flexibility.
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics, Inc.’s price range in the past 12 months?
Context Therapeutics, Inc. lowest stock price was $0.56 and its highest was $3.62 in the past 12 months.
What is Context Therapeutics, Inc.’s market cap?
Context Therapeutics, Inc.’s market cap is $58.06M.
When is Context Therapeutics, Inc.’s upcoming earnings report date?
Context Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 52 days.
How were Context Therapeutics, Inc.’s earnings last quarter?
Context Therapeutics, Inc. released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.111 by $0.021.
Is Context Therapeutics, Inc. overvalued?
According to Wall Street analysts Context Therapeutics, Inc.’s price is currently Undervalued.
Does Context Therapeutics, Inc. pay dividends?
Context Therapeutics, Inc. does not currently pay dividends.
What is Context Therapeutics, Inc.’s EPS estimate?
Context Therapeutics, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Context Therapeutics, Inc. have?
Context Therapeutics, Inc. has 91,879,170 shares outstanding.
What happened to Context Therapeutics, Inc.’s price movement after its last earnings report?
Context Therapeutics, Inc. reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.111. Following the earnings report the stock price went down -3.32%.
Which hedge fund is a major shareholder of Context Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (133.20% Upside)
$5.67 (133.20% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 37.1%
Last 30 Days ▲ 33.0%
Last 30 Days ▲ 33.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.07%
12-Months-Change
Fundamentals
Return on Equity
-59.95%
Trailing 12-Months
Asset Growth
-36.69%
Trailing 12-Months
Company Description
Context Therapeutics, Inc.
Context Therapeutics Inc. (CNTX) is a biopharmaceutical firm in the clinical development stage, dedicated to advancing cancer treatments specifically for women in the United States. Its leading investigational therapy is onapristone extended release (ONA-XR). This compound functions as a potent and selective antagonist of the progesterone receptor, aiming to counteract the resistance often encountered with various cancer therapeutics, particularly anti-estrogen therapies, in hormone-dependent female cancers. The company is also progressing with CLDN6xCD3 bsAb, a bispecific monoclonal antibody designed to target both CD3 and Claudin 6 antigens. Its mechanism involves redirecting T-cell-mediated destruction towards malignant cells that express CLDN6. Furthermore, Context Therapeutics Inc. holds a collaboration and licensing agreement with Integral Molecular, Inc. This partnership focuses on the development of an anti-claudin 6 bispecific monoclonal antibody for the treatment of gynecologic cancers. Established in 2015, Context Therapeutics Inc. operates out of its headquarters in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$5.67
▲(133.20% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
5.87% Mutual Funds
62.64% Other Institutional Investors
26.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---